{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:01:22Z","timestamp":1762124482017,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006832","name":"Center for HIV\/AIDS Educational Studies and Training, Hunter College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.chest.2018.12.002","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T14:01:01Z","timestamp":1554386461000},"page":"e79-e82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Exacerbation of Previously Undiagnosed Bird Fancier\u2019s Lung by Pembrolizumab Therapy"],"prefix":"10.1016","volume":"155","author":[{"given":"Ann","family":"Vu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.chest.2018.12.002_bib1","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrclinonc.2014.174","article-title":"Decade in review\u2014cancer immunotherapy: entering the mainstream of cancer treatment","volume":"11","author":"Rosenberg","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.chest.2018.12.002_bib2","first-page":"9585614","article-title":"Immunotherapies: exploiting the immune system for cancer treatment","volume":"2018","author":"Koury","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.chest.2018.12.002_bib3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/TCRM.S143939","article-title":"Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis","volume":"13","author":"Cui","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.chest.2018.12.002_bib4","first-page":"357","article-title":"Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway","volume":"7","author":"Momtaz","year":"2014","journal-title":"Pharmgenomics Pers Med"},{"issue":"12","key":"10.1016\/j.chest.2018.12.002_bib5","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5502","key":"10.1016\/j.chest.2018.12.002_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in\u00a0PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.chest.2018.12.002_bib7","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.chest.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.chest.2018.12.002_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218328617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369218328617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:59:01Z","timestamp":1762124341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369218328617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0012369218328617"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2018.12.002","relation":{},"ISSN":["0012-3692"],"issn-type":[{"type":"print","value":"0012-3692"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exacerbation of Previously Undiagnosed Bird Fancier\u2019s Lung by Pembrolizumab Therapy","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}